CorMedix Inc (CRMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $370.64M
Last updated: Nov 17, 2026 at 11:05 AM ET
CorMedix Inc (CRMD) Earnings: Report Dates and Results
CorMedix (CRMD) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, CorMedix reported EPS of -$0.04, above the -$0.09 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRMD has an expected report date of Mar 3, 2027.
CRMD Earnings Call
The latest CRMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CRMD beat 25, missed 13 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $54.52M, down 47.7% from $104.28M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.04 | -$0.09 | -$0.20 - -$0.05 | +55.56% | Beat | -102.8% | 6 | 1 up, 2 down | Nov 12, 2026 | $54.52M |
| Jun 30, 2026 | $0.29 | $0.26 | $0.15 - $0.33 | +11.54% | Beat | +3.6% | 5 | 1 up, 0 down | Aug 13, 2026 | $101.93M |
| Mar 31, 2026 | $0.35 | $0.33 | $0.33 - $0.33 | +6.06% | Beat | +16.7% | 2 | 0 up, 0 down | May 14, 2026 | $127.43M |
| Dec 31, 2025 | $0.16 | $0.74 | $0.67 - $0.97 | -78.24% | Miss | -27.2% | 3 | 0 up, 1 down | Mar 5, 2026 | $118.37M |
| Sep 30, 2025 | $1.41 | $0.63 | $0.30 - $1.02 | +123.81% | Beat | N/A | 7 | 2 up, 0 down | Nov 12, 2025 | $104.28M |
| Jun 30, 2025 | $0.28 | $0.20 | $0.06 - $0.25 | +40.00% | Beat | N/A | 7 | 4 up, 0 down | Aug 7, 2025 | $39.74M |
| Mar 31, 2025 | $0.30 | $0.25 | $0.17 - $0.30 | +20.00% | Beat | N/A | 6 | 4 up, 0 down | May 6, 2025 | $39.08M |
| Dec 31, 2024 | $0.22 | $0.14 | $0.05 - $0.21 | +57.14% | Beat | N/A | 5 | 3 up, 0 down | Mar 25, 2025 | $31.21M |
| Sep 30, 2024 | -$0.05 | -$0.10 | -$0.13 - -$0.06 | +50.00% | Beat | N/A | 4 | 0 up, 0 down | Oct 30, 2024 | $11.46M |
| Jun 30, 2024 | -$0.25 | -$0.25 | -$0.27 - -$0.23 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Aug 14, 2024 | $806119 |
| Mar 31, 2024 | -$0.25 | -$0.28 | -$0.32 - -$0.25 | +10.71% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.26 | -$0.20 | -$0.21 - -$0.18 | -30.00% | Miss | N/A | 4 | 0 up, 0 down | Mar 12, 2024 | $304110 |
| Sep 30, 2023 | -$0.17 | -$0.21 | -$0.23 - -$0.19 | +19.05% | Beat | N/A | 4 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$0.25 | -$0.24 | -$0.26 - -$0.22 | -4.17% | Miss | N/A | 3 | 0 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$0.24 | -$0.20 | -$0.20 - -$0.20 | -20.00% | Miss | N/A | 3 | 0 up, 0 down | May 15, 2023 | N/A |
| Dec 31, 2022 | -$0.20 | -$0.19 | -$0.20 - -$0.17 | -5.26% | Miss | N/A | 3 | 0 up, 0 down | Mar 30, 2023 | $29702 |
| Sep 30, 2022 | -$0.17 | -$0.23 | -$0.25 - -$0.20 | +26.09% | Beat | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | $6817 |
| Jun 30, 2022 | -$0.19 | -$0.21 | -$0.21 - -$0.20 | +9.52% | Beat | N/A | 3 | 0 up, 0 down | Aug 11, 2022 | $21253 |
| Mar 31, 2022 | -$0.18 | -$0.22 | N/A | +18.18% | Beat | N/A | 3 | 3 up, 0 down | May 12, 2022 | $7636 |
| Dec 31, 2021 | -$0.20 | -$0.23 | -$0.27 - -$0.21 | +13.04% | Beat | N/A | 3 | 0 up, 0 down | Mar 29, 2022 | $56396 |
| Sep 30, 2021 | -$0.22 | -$0.18 | -$0.18 - -$0.17 | -22.22% | Miss | N/A | 3 | 2 up, 0 down | Nov 9, 2021 | $38088 |
| Jun 30, 2021 | -$0.12 | -$0.19 | -$0.22 - -$0.13 | +36.84% | Beat | N/A | 4 | N/A | Aug 12, 2021 | $8191 |
| Mar 31, 2021 | -$0.20 | -$0.18 | -$0.20 - -$0.16 | -11.11% | Miss | N/A | 5 | N/A | May 13, 2021 | $88261 |
| Dec 31, 2020 | -$0.19 | -$0.22 | -$0.25 - -$0.21 | +13.64% | Beat | N/A | 5 | N/A | Mar 30, 2021 | $55713 |
| Sep 30, 2020 | -$0.22 | -$0.25 | -$0.30 - -$0.22 | +12.00% | Beat | N/A | 4 | N/A | Nov 5, 2020 | $93020 |
| Jun 30, 2020 | -$0.14 | -$0.24 | -$0.24 - -$0.04 | +41.67% | Beat | N/A | 2 | N/A | Aug 10, 2020 | $16443 |
| Mar 31, 2020 | -$0.21 | -$0.23 | -$0.23 - -$0.23 | +8.70% | Beat | N/A | 2 | N/A | May 11, 2020 | $74054 |
| Dec 31, 2019 | -$0.21 | -$0.24 | -$0.25 - -$0.23 | +12.50% | Beat | -310.0% | 2 | N/A | Mar 16, 2020 | $24778 |
| Sep 30, 2019 | -$0.22 | -$0.25 | -$0.25 - -$0.25 | +12.00% | Beat | N/A | 2 | N/A | Nov 14, 2019 | $59530 |
| Jun 30, 2019 | -$0.24 | -$0.21 | -$0.22 - -$0.21 | -14.29% | Miss | N/A | 2 | N/A | Aug 13, 2019 | $35266 |
| Mar 31, 2019 | -$0.22 | -$0.28 | -$0.29 - -$0.28 | +21.43% | Beat | N/A | 2 | N/A | May 13, 2019 | $163692 |
| Dec 31, 2018 | $0.10 | -$0.40 | -$0.50 - -$0.30 | +125.00% | Beat | N/A | 2 | N/A | Mar 14, 2019 | $26522 |
| Sep 30, 2018 | -$0.55 | -$0.30 | N/A | -83.33% | Miss | N/A | N/A | N/A | Nov 14, 2018 | $372514 |
| Jun 30, 2018 | -$0.50 | -$0.50 | -$0.50 - -$0.50 | 0.00% | In line | N/A | 1 | N/A | Aug 14, 2018 | $7551 |
| Mar 31, 2018 | -$0.70 | -$0.50 | -$0.50 - -$0.50 | -40.00% | Miss | N/A | 1 | N/A | May 15, 2018 | $23210 |
| Dec 31, 2017 | -$0.77 | -$0.60 | -$0.60 - -$0.60 | -28.33% | Miss | N/A | 1 | N/A | Mar 19, 2018 | $92525 |
| Sep 30, 2017 | -$0.66 | -$0.65 | N/A | -1.54% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $61075 |
| Jun 30, 2017 | -$0.67 | -$0.80 | N/A | +16.25% | Beat | N/A | N/A | N/A | Aug 9, 2017 | $136168 |
| Mar 31, 2017 | -$0.95 | -$0.72 | N/A | -31.94% | Miss | N/A | N/A | N/A | May 10, 2017 | $39559 |
| Dec 31, 2016 | -$0.80 | -$1.07 | N/A | +25.23% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $121716 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.15, a profit after a loss of $0.33 per share the year before. It was -$3.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.15 | N/A |
| Dec 31, 2024 | -$0.33 | N/A |
| Dec 31, 2023 | -$0.92 | N/A |
| Dec 31, 2022 | -$0.74 | N/A |
| Dec 31, 2021 | -$0.74 | N/A |
| Dec 31, 2020 | -$0.76 | N/A |
| Dec 31, 2019 | -$0.89 | N/A |
| Dec 31, 2018 | -$1.65 | N/A |
| Dec 31, 2017 | -$3.05 | N/A |
| Dec 31, 2016 | -$3.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,282 | 10 | |
| 2026Q2 | Jun 30, 2026 | 3,753 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,860 | 12 | |
| 2025Q4 | Dec 31, 2025 | 4,155 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,162 | 10 | |
| 2025Q2 | Jun 30, 2025 | 3,623 | 10 | |
| 2025Q1 | Mar 31, 2025 | 4,102 | 9 | |
| 2024Q4 | Dec 31, 2024 | 4,838 | 11 |
2026Q3 Earnings Call
Opening remarks
Daniel Ferry Representative, Life Science Advisors Good morning, and welcome to the CorMedix Third Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chairman and Chief Executive Officer of CorMedix. He is joined by Susan Blum, EVP and Chief Financial Officer. In addition, Liz Hurlburt, EVP and Chief Commercial Officer, and Beth Zelnick Kaufman, EVP and Chief Legal and Compliance Officer and Corporate Secretary, will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, we may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position. Actual results may differ materially from the estimates on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CorMedix's filings with the SEC, which are available free of charge on the SEC's website or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements, and investors should not place undue reliance on these statements. CorMedix does not intend to update these forward-looking statements except as required by law. On this call, the company will discuss certain non-GAAP measures of its performance. GAAP-to-non-GAAP financial reconciliations and supplemental financial information are provided in CorMedix's earnings release and the current report on Form 8-K filed with the SEC. This information is also available on the Investor Relations section of CorMedix's website. In addition, today's discussion includes statements regarding CorMedix's proposed acquisition of substantially all the assets of Heron Therapeutics, which remains subject to approval by Heron's stockholders, regulatory clearance, and other customary closing conditions. CorMedix has filed a current report on Form 8-K describing the proposed transaction in greater detail. Investors are urged to read it and any other relevant documents CorMedix has filed with the SEC carefully and in their entirety because they contain important information about the proposed transaction. At this time, it is now my pleasure to turn the call over to Joe Todisco, Chairman and Chief Executive Officer of CorMedix. Joe, please go ahead.
Joseph Todisco Chairman and CEO Thanks, Daniel. Good morning, everyone, and thank you for joining us on this call. On Monday, we announced the definitive agreement to acquire substantially all of the assets of Heron Therapeutics, encompassing both commercial and pipeline assets that we believe are highly complementary and synergistic with CorMedix's growth strategy in institutional settings of care. As we discussed on Monday, we see four pillars to the strategic rationale for this transaction.
Frequently Asked Questions About CRMD
When is CorMedix's next earnings date?
CorMedix's next earnings report is expected for Mar 3, 2027.
Did CRMD beat earnings estimates last quarter?
Yes. CorMedix reported EPS of -$0.04 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 55.56% surprise.
What EPS do analysts expect from CRMD next quarter?
The consensus EPS estimate for CorMedix for the quarter ending Dec 31, 2026 is -$0.17 from 7 analysts, with estimates from -$0.25 to -$0.13.
How often does CRMD beat earnings estimates?
CorMedix beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +29.48%.
CRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors